NCT01518036View on ClinicalTrials.gov

Use of Somatropin in Turner Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

September 14, 1987

Primary Completion Date

April 11, 2004

Study Completion Date

April 11, 2004

Conditions
Genetic DisorderTurner Syndrome
Interventions
DRUG

somatropin

2.9 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached

DRUG

somatropin

4.3 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached

Trial Locations (1)

RH11 9RT

Novo Nordisk Investigational Site, Crawley

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01518036 - Use of Somatropin in Turner Syndrome | Biotech Hunter | Biotech Hunter